A Phase II Study of Alpha Interferon (alphaIFN) In HIV-Related Malignancies - A Pediatric Oncology Group Wide Study

Date de début de l'étude : 1 décembre 1994

DISEASE CHARACTERISTICS: Histologically proven malignancy diagnosed at any time following confirmation of HIV-positivity, including the following: Leukemia Non-Hodgkin's lymphoma CNS lymphoma Other solid tumors Measurable disease Concurrent registration on protocol POG-9182 required Confirmed HIV-positive by POG-9182 criteria Required biology studies completed PATIENT CHARACTERISTICS: Age: 21 and under Performance status: Not specified Life expectancy: More than 4 weeks Hematopoietic: Absolute neutrophil count at least 1,000/mm^3 Platelet count at least 100,000/mm^3 (unless bone marrow involvement present) Hepatic: See Disease Characteristics Bilirubin less than 1.5 times normal SGPT and SGOT less than 2 times normal (may discuss with Study Coordinator) Renal: Creatinine less than 1.5 mg/dL Cardiovascular: Adequate cardiac function by echocardiogram/MUGA scan Other: Chronically infected patients must be stable enough to meet life expectancy requirement PRIOR CONCURRENT THERAPY: Biologic therapy: No prior interferon for cancer Prior interferon alfa for viral infections (i.e., hepatitis) must be discussed with Study Coordinator Chemotherapy: At least 1 week since prior chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 1 week since prior radiotherapy Surgery: Not specified Other: Prior antiretroviral therapy allowed At least 1 week since prior acute treatment for any serious or life-threatening infection No concurrent local treatment unless discussed with the Study Coordinator No concurrent acute treatment for any serious or life-threatening infection Concurrent antiretroviral therapy allowed